Transport
Centra Health INC
Centra Health INC was paid $78.57M by Medicaid between Jan 2018 and Dec 2024, across 493 billing codes. Its largest line is 99285, emergency room visit (most serious) — 12% of everything it billed.
33Billing provider infoCENTRA HEALTH INC
LYNCHBURG, VA 24503
LYNCHBURG, VA 24503
33aNPI1770693939assigned 08/30/2006
33bProvider typeAir Ambulance
28Total paid$78.57M
24GClaims2,251,014
24DCodes billed493
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Air Ambulance providers in Virginia
Rank by total paid#1 of 11
Median peer was paid$171K
This provider vs. median460×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ADDISON, LEWIS controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 293,693 | $6.46M | |
| 2019 | 323,577 | $8.29M | |
| 2020 | 269,922 | $8.83M | |
| 2021 | 274,581 | $8.75M | |
| 2022 | 333,830 | $12.64M | |
| 2023 | 440,210 | $18.44M | |
| 2024incomplete | 315,201 | $15.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 57,021 | 48,154 | $9.05M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 32,260 | 23,907 | $9.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 51,678 | 44,890 | $8.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 50,612 | 45,224 | $8.13M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 11,077 | 9,834 | $2.59M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.6% | 43,101 | 32,501 | $2.07M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.5% | 442 | 296 | $2.00M |
| G0378 | Hospital observation service, per hour | 2.2% | 11,452 | 9,130 | $1.76M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 7,268 | 6,490 | $1.68M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.1% | 25,244 | 23,260 | $1.63M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 11,523 | 10,114 | $1.59M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 15,142 | 10,021 | $1.58M |
481 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 2.0% | 11,345 | $1.57M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 11,044 | $1.14M |
| 59025 | Fetal non-stress test | 1.4% | 6,077 | $1.13M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 7,425 | $1.09M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 8,632 | $1.07M |
| A0425 | Ground mileage, per statute mile | 1.2% | 30,226 | $944K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 4,276 | $871K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 4,772 | $810K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 18,562 | $778K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,681 | $757K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,258 | $750K |
| 80053 | Comprehensive metabolic panel | <1% | 119,729 | $671K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,175 | $609K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 5,407 | $549K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 932 | $520K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,592 | $465K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 6,141 | $451K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,156 | $443K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 7,643 | $421K |
| T2005 | Non-emergency transportation; stretcher van | <1% | 1,390 | $402K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 584 | $392K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,932 | $377K |
| 76641 | <1% | 3,117 | $364K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 5,146 | $356K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 15,843 | $311K |
| 93971 | <1% | 3,840 | $303K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,786 | $301K |
| 70496 | <1% | 1,330 | $298K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,481 | $292K |
| 93320 | <1% | 820 | $267K | |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | <1% | 404 | $265K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,852 | $260K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,470 | $257K |
| 36415 | Collection of venous blood by venipuncture | <1% | 66,415 | $256K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,090 | $242K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,514 | $202K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 159 | $202K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 45,828 | $199K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 4,682 | $195K |
| 76642 | <1% | 1,851 | $194K | |
| 96415 | <1% | 953 | $190K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,226 | $189K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 32,496 | $185K |
| 96416 | <1% | 761 | $183K | |
| 93017 | <1% | 1,832 | $173K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 2,566 | $168K |
| 36430 | <1% | 960 | $164K | |
| 12001 | <1% | 741 | $156K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 550 | $153K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 115,788 | $146K |
| A0130 | Non-emergency transportation: wheelchair van | <1% | 3,602 | $145K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 50,190 | $145K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 765 | $132K |
| 77336 | <1% | 1,740 | $129K | |
| 93325 | <1% | 2,156 | $126K | |
| 93970 | <1% | 1,180 | $123K | |
| 49083 | <1% | 263 | $122K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 635 | $120K |
| 77066 | Tomosynthesis, mammo | <1% | 3,178 | $117K |
| 93321 | <1% | 513 | $112K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,589 | $106K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 29,342 | $106K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,784 | $101K |
| 97161 | <1% | 1,632 | $101K | |
| 99070 | <1% | 5,288 | $100K | |
| 27447 | <1% | 12 | $98K | |
| 77386 | <1% | 334 | $97K | |
| 76801 | <1% | 2,313 | $96K | |
| 93351 | <1% | 220 | $93K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 573 | $90K |
| 70498 | <1% | 1,710 | $89K | |
| 96523 | <1% | 1,908 | $89K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 2,159 | $88K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,160 | $86K |
| A0436 | Rotary wing air mileage, per statute mile | <1% | 406 | $86K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,713 | $84K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 26,057 | $82K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 2,426 | $82K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,580 | $81K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,905 | $80K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,427 | $72K |
| 10060 | <1% | 630 | $70K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,424 | $67K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,065 | $66K |
| 76770 | <1% | 767 | $65K | |
| 93308 | <1% | 253 | $65K | |
| 83880 | <1% | 9,692 | $65K | |
| 93350 | <1% | 191 | $64K | |
| 80061 | Lipid panel | <1% | 12,555 | $61K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 35,138 | $57K |
| 82962 | <1% | 28,593 | $53K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,707 | $52K |
| 93246 | <1% | 1,984 | $52K | |
| 77412 | <1% | 187 | $50K | |
| 93976 | <1% | 1,124 | $48K | |
| 12002 | <1% | 254 | $48K | |
| 90715 | <1% | 2,787 | $46K | |
| 93925 | <1% | 454 | $44K | |
| 84484 | <1% | 36,063 | $44K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 4,264 | $43K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 20,231 | $42K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 290 | $42K |
| 96367 | <1% | 7,597 | $41K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,987 | $41K |
| 93000 | <1% | 11,808 | $39K | |
| 70491 | <1% | 176 | $39K | |
| 93458 | <1% | 29 | $36K | |
| 12011 | <1% | 199 | $36K | |
| 85027 | <1% | 36,242 | $35K | |
| 80320 | <1% | 6,092 | $35K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,670 | $34K |
| 71250 | <1% | 737 | $34K | |
| 80329 | <1% | 4,051 | $34K | |
| 81001 | <1% | 61,556 | $33K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 24,235 | $31K |
| 51798 | <1% | 1,773 | $30K | |
| 29125 | <1% | 497 | $30K | |
| 86900 | <1% | 8,503 | $29K | |
| 81003 | <1% | 2,315 | $29K | |
| 87040 | <1% | 5,686 | $28K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,997 | $27K |
| 97165 | <1% | 485 | $26K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 34,337 | $26K |
| 74018 | <1% | 2,702 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,690 | $24K |
| J3490 | Unclassified drugs | <1% | 19,328 | $24K |
| 97116 | <1% | 999 | $24K | |
| 85610 | <1% | 17,166 | $23K | |
| 77001 | <1% | 367 | $23K | |
| 82607 | <1% | 4,955 | $23K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 232 | $22K |
| 72100 | <1% | 3,104 | $21K | |
| 86850 | <1% | 7,233 | $21K | |
| 76870 | <1% | 265 | $21K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 417 | $21K |
| 80047 | <1% | 5,640 | $21K | |
| 93880 | <1% | 238 | $20K | |
| 76830 | Ultrasound, transvaginal | <1% | 301 | $20K |
| 85380 | <1% | 5,526 | $19K | |
| 87081 | <1% | 11,451 | $19K | |
| 84439 | <1% | 4,802 | $18K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 56 | $17K |
| 73030 | <1% | 3,015 | $16K | |
| 93304 | <1% | 102 | $16K | |
| 80361 | <1% | 935 | $16K | |
| 82728 | <1% | 3,587 | $16K | |
| 70486 | <1% | 714 | $16K | |
| C1776 | Joint device (implantable) | <1% | 170 | $15K |
| 83970 | <1% | 1,124 | $15K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 432 | $15K |
| 84702 | <1% | 5,909 | $15K | |
| 19083 | <1% | 13 | $14K | |
| 86780 | <1% | 2,126 | $13K | |
| 95811 | <1% | 28 | $13K | |
| 81025 | <1% | 10,217 | $13K | |
| 77061 | <1% | 237 | $13K | |
| 86803 | <1% | 2,804 | $12K | |
| 93975 | <1% | 80 | $12K | |
| 73130 | <1% | 2,238 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 268 | $12K |
| 82570 | <1% | 3,553 | $12K | |
| 95806 | <1% | 160 | $12K | |
| A4649 | Surgical supply; miscellaneous | <1% | 768 | $12K |
| 77334 | <1% | 90 | $11K | |
| 93242 | <1% | 325 | $11K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 904 | $11K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 44 | $11K |
| 36561 | <1% | 12 | $11K | |
| 73564 | <1% | 2,773 | $11K | |
| 73610 | <1% | 2,643 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,158 | $10K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 12,451 | $10K |
| 74174 | <1% | 56 | $10K | |
| 83605 | <1% | 10,997 | $10K | |
| 73630 | <1% | 2,849 | $10K | |
| 0296T | <1% | 966 | $9K | |
| 93922 | <1% | 124 | $9K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 490 | $9K |
| 86901 | <1% | 8,548 | $9K | |
| 85347 | <1% | 237 | $9K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 24 | $9K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,468 | $9K |
| 83550 | <1% | 3,267 | $8K | |
| 80050 | General health panel | <1% | 365 | $8K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 85 | $8K |
| 80076 | <1% | 3,001 | $8K | |
| 83540 | <1% | 3,745 | $8K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 824 | $8K |
| 83735 | <1% | 15,956 | $8K | |
| 87070 | <1% | 3,651 | $8K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 173 | $8K |
| 82803 | <1% | 7,262 | $8K | |
| 82565 | <1% | 3,472 | $8K | |
| 93296 | <1% | 650 | $8K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 146 | $7K |
| J0897 | Injection, denosumab, 1 mg | <1% | 15 | $7K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 473 | $7K |
| 83690 | <1% | 23,239 | $7K | |
| 93798 | <1% | 61 | $7K | |
| C1769 | Guide wire | <1% | 4,330 | $7K |
| 87186 | <1% | 7,561 | $7K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 63 | $7K |
| 76937 | <1% | 199 | $7K | |
| 64483 | <1% | 13 | $6K | |
| 87077 | <1% | 4,765 | $6K | |
| 76536 | <1% | 67 | $6K | |
| 97597 | <1% | 325 | $6K | |
| 72070 | <1% | 803 | $6K | |
| 80164 | <1% | 1,296 | $6K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $6K |
| 72131 | <1% | 84 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,933 | $6K |
| 86140 | <1% | 4,660 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 15,676 | $6K |
| 51702 | <1% | 627 | $6K | |
| 87340 | <1% | 2,511 | $6K | |
| 87088 | <1% | 5,655 | $6K | |
| 86762 | <1% | 1,251 | $6K | |
| 0002A | <1% | 172 | $6K | |
| 73502 | <1% | 2,052 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 33,439 | $5K |
| 10061 | <1% | 32 | $5K | |
| 77300 | <1% | 71 | $5K | |
| 80074 | <1% | 339 | $5K | |
| 0001A | <1% | 179 | $5K | |
| 81015 | <1% | 1,568 | $5K | |
| 75574 | <1% | 15 | $5K | |
| 82247 | <1% | 1,835 | $5K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 148 | $5K |
| 96411 | <1% | 696 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,725 | $4K |
| 96417 | <1% | 2,745 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,036 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,482 | $4K |
| 87807 | <1% | 1,764 | $4K | |
| 96376 | <1% | 9,166 | $4K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 742 | $4K |
| 73718 | <1% | 15 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 20,773 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,194 | $4K |
| 71271 | <1% | 37 | $4K | |
| 90686 | <1% | 249 | $4K | |
| 96401 | <1% | 85 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,002 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,109 | $4K |
| 73110 | <1% | 1,309 | $4K | |
| 74022 | <1% | 1,403 | $3K | |
| 87147 | <1% | 4,371 | $3K | |
| 83020 | <1% | 363 | $3K | |
| 80069 | <1% | 1,108 | $3K | |
| 86592 | <1% | 1,632 | $3K | |
| 85007 | <1% | 5,677 | $3K | |
| 94664 | <1% | 1,578 | $3K | |
| 86618 | <1% | 562 | $3K | |
| 85018 | <1% | 1,500 | $3K | |
| 85651 | <1% | 3,052 | $3K | |
| 73140 | <1% | 580 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,560 | $3K |
| 73090 | <1% | 818 | $3K | |
| 86008 | <1% | 371 | $3K | |
| 72170 | <1% | 974 | $3K | |
| 94375 | <1% | 25 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 72 | $3K |
| 84703 | <1% | 2,254 | $3K | |
| 73590 | <1% | 1,105 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 22,603 | $3K |
| 82784 | <1% | 268 | $3K | |
| 84550 | <1% | 2,958 | $2K | |
| 84145 | <1% | 1,259 | $2K | |
| 87205 | <1% | 3,421 | $2K | |
| 83615 | <1% | 10,032 | $2K | |
| 85014 | <1% | 5,302 | $2K | |
| 80349 | <1% | 237 | $2K | |
| T2049 | Non-emergency transportation; stretcher van, mileage; per mile | <1% | 1,390 | $2K |
| 85730 | <1% | 5,571 | $2K | |
| J2770 | Injection, quinupristin/dalfopristin, 500 mg (150/350) | <1% | 57 | $2K |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,180 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 24,061 | $2K |
| 86923 | <1% | 240 | $2K | |
| 84156 | <1% | 2,671 | $2K | |
| 86038 | <1% | 375 | $2K | |
| 86757 | <1% | 226 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 283 | $2K |
| 83655 | <1% | 139 | $2K | |
| 72141 | <1% | 13 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,488 | $2K |
| 76857 | <1% | 16 | $2K | |
| 99152 | <1% | 2,105 | $2K | |
| 72110 | <1% | 108 | $2K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 23 | $2K |
| 86787 | <1% | 344 | $2K | |
| 87493 | <1% | 194 | $2K | |
| 87210 | <1% | 4,369 | $2K | |
| 71101 | <1% | 245 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 372 | $1K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 956 | $1K |
| 73560 | <1% | 260 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 5,847 | $1K |
| 82550 | <1% | 2,761 | $1K | |
| 86706 | <1% | 481 | $1K | |
| 82746 | <1% | 492 | $1K | |
| 84152 | <1% | 115 | $1K | |
| 84481 | <1% | 182 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,931 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,627 | $1K |
| 86704 | <1% | 308 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,395 | $1K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 16 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,056 | $1K |
| 84100 | <1% | 3,033 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,843 | $1K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 356 | $1K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,603 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 329 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19,666 | $1K |
| 76820 | <1% | 19 | $1K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 68 | $1K |
| 82043 | <1% | 659 | $1K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 38 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 42 | $1K |
| 51701 | <1% | 64 | $1K | |
| 83516 | <1% | 198 | $1K | |
| 82947 | <1% | 1,311 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 386 | $996.37 |
| 29515 | <1% | 33 | $988.98 | |
| 86666 | <1% | 319 | $979.01 | |
| 73080 | <1% | 425 | $961.99 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,771 | $925.48 |
| 85652 | <1% | 1,460 | $924.31 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 7,280 | $924.12 |
| 72040 | <1% | 68 | $921.54 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,032 | $871.42 |
| 80321 | <1% | 29 | $804.69 | |
| 84146 | <1% | 46 | $794.36 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,243 | $791.47 |
| 75571 | <1% | 16 | $784.15 | |
| 77062 | <1% | 32 | $781.50 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 74 | $774.56 |
| 80178 | <1% | 163 | $745.08 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 145 | $721.88 |
| 36600 | <1% | 188 | $716.89 | |
| 84403 | <1% | 43 | $676.54 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,913 | $667.48 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,581 | $636.49 |
| 87045 | <1% | 400 | $625.95 | |
| 93226 | <1% | 19 | $623.91 | |
| 82785 | <1% | 47 | $606.98 | |
| 93290 | <1% | 48 | $590.92 | |
| 89055 | <1% | 302 | $578.26 | |
| 86431 | <1% | 135 | $569.45 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 356 | $548.89 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 937 | $504.66 |
| 87641 | <1% | 29 | $491.31 | |
| 87184 | <1% | 1,386 | $487.28 | |
| 84132 | <1% | 2,059 | $445.58 | |
| 93270 | <1% | 13 | $408.90 | |
| 90656 | <1% | 16 | $398.09 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 1,452 | $395.47 |
| 96368 | <1% | 1,387 | $366.95 | |
| 73562 | <1% | 80 | $348.62 | |
| 76000 | <1% | 165 | $331.91 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,329 | $323.47 |
| 87046 | <1% | 400 | $311.10 | |
| 73100 | <1% | 116 | $305.31 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,108 | $285.38 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,005 | $264.58 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,164 | $252.04 |
| 83631 | <1% | 13 | $249.93 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 262 | $242.56 |
| 94644 | <1% | 57 | $224.02 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 17 | $217.95 |
| 85045 | <1% | 351 | $215.41 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,046 | $214.57 |
| 80143 | <1% | 488 | $207.80 | |
| 82378 | <1% | 77 | $197.27 | |
| 73060 | <1% | 140 | $192.39 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,763 | $192.19 |
| 84165 | <1% | 75 | $185.48 | |
| 83001 | <1% | 14 | $176.94 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 447 | $173.73 |
| 86003 | <1% | 26 | $172.46 | |
| 82150 | <1% | 45 | $167.81 | |
| 90662 | <1% | 48 | $167.45 | |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | <1% | 55 | $165.55 |
| 82140 | <1% | 191 | $163.51 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 681 | $155.53 |
| 84425 | <1% | 26 | $147.41 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,991 | $146.01 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,317 | $137.59 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 744 | $134.21 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,153 | $133.67 |
| 82248 | <1% | 114 | $130.03 | |
| 86308 | <1% | 87 | $128.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 891 | $125.72 |
| 87328 | <1% | 26 | $123.13 | |
| 86753 | <1% | 106 | $119.11 | |
| 80179 | <1% | 475 | $118.92 | |
| 80197 | <1% | 28 | $117.28 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,695 | $110.50 |
| 82330 | <1% | 185 | $107.22 | |
| 80373 | <1% | 17 | $96.83 | |
| 72050 | <1% | 27 | $91.85 | |
| 87329 | <1% | 26 | $91.62 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,729 | $90.54 |
| 93282 | <1% | 20 | $85.56 | |
| 84153 | <1% | 16 | $83.54 | |
| 84295 | <1% | 187 | $76.18 | |
| 83721 | <1% | 15 | $72.66 | |
| 73552 | <1% | 150 | $71.37 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 680 | $67.22 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,950 | $61.53 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,358 | $55.32 |
| 83021 | <1% | 58 | $47.01 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,639 | $46.84 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 706 | $44.98 |
| 93280 | <1% | 15 | $40.36 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,121 | $40.07 |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 1,139 | $39.58 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,986 | $37.08 |
| 73600 | <1% | 17 | $36.76 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,531 | $31.91 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 18 | $29.94 |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | <1% | 625 | $29.24 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 527 | $25.98 |
| 87075 | <1% | 13 | $25.79 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,783 | $22.43 |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard | <1% | 1,060 | $19.78 |
| 89051 | <1% | 74 | $18.69 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 766 | $15.03 |
| 93299 | <1% | 14 | $12.40 | |
| 85384 | <1% | 29 | $11.34 | |
| 86320 | <1% | 15 | $8.75 | |
| 81000 | <1% | 12 | $3.69 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 301 | $1.92 |
| J7999 | Compounded drug, not otherwise classified | <1% | 748 | $1.26 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 120 | $0.98 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 33 | $0.44 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 17 | $0.26 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 325 | $0.24 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 33 | $0.23 |
| 88342 | 0% | 47 | $0.00 | |
| 74420 | 0% | 59 | $0.00 | |
| 36416 | 0% | 242 | $0.00 | |
| 94760 | 0% | 60 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 212 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 445 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 46 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 28 | $0.00 |
| 73660 | 0% | 15 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 101 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 237 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 34 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 111 | $0.00 |
| 71020 | 0% | 17 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 16 | $0.00 |
| 94660 | 0% | 105 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 33 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 39 | $0.00 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 15 | $0.00 |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 78 | $0.00 |
| 96377 | 0% | 35 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 33 | $0.00 |
| 73620 | 0% | 16 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 22 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 449 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,702 | $0.00 |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 0% | 178 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 268 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 15 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 608 | $0.00 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 177 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 142 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 306 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 54 | $0.00 |
| 73070 | 0% | 14 | $0.00 | |
| 96402 | 0% | 30 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 26 | $0.00 |
| A6198 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 48 sq. in., each dressing | 0% | 14 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 12 | $0.00 |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 14 | $0.00 |
| C1876 | Stent, non-coated/non-covered, with delivery system | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialADDISON, LEWIS (CFO)
| Provider | Location | Paid |
|---|---|---|
| Centra Medical Group, LLC | Lynchburg, VA | $60.16M |
| Centra Health INC | Lynchburg, VA | $18.47M |
| Centra Health INC | Lynchburg, VA | $5.20M |
| Centra Health INC | Lynchburg, VA | $2.82M |
| Centra Health INC | Lynchburg, VA | $2.35M |
| Centra Health INC | Lynchburg, VA | $2.04M |
| Centra Health INC | Lynchburg, VA | $1.59M |
| Centra Health INC | Lynchburg, VA | $205K |
| Centra Health, INC. | Lynchburg, VA | $13K |
| Centra Medical Group, LLC | Lynchburg, VA | $12K |
| Centra Health INC | Lynchburg, VA | $7K |
| Centra Medical Group, LLC | Lynchburg, VA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.